Pacheco S, Rodríguez J, Briceño E, Martínez J, Guerra JF, Jarufe N

Idioma: Español
Referencias bibliográficas: 25
Paginas: 321-327
Archivo PDF: 259.08 Kb.

RESUMEN

Objetivo: Determinar la sobrevida global de los pacientes sometidos a trasplante hepático (TH) por carcinoma hepatocelular (CHC) siguiendo los criterios de Milán (CM), y analizar los factores asociados a la sobrevida. Método: Estudio de cohorte no concurrente. Se analizaron los pacientes sometidos a TH por CHC entre los años 2000 y 2016. Se realizó un análisis de los factores asociados a la sobrevida mediante Kaplan-Meier, test de log-rank y regresión de Cox. Se consideró significativo un valor de p ‹ 0.05. Resultados: Se realizaron 50 TH por CHC. El promedio de edad fue de 60.8 ± 6.1 años; 38 pacientes (76%) fueron de sexo masculino. En el análisis multivariable, los factores asociados a la sobrevida fueron el cumplimiento de los CM (hazard ratio [HR]: 0.104; intervalo de confianza del 95% [IC 95%]: 0.017-0.637; p = 0.01) y la ausencia de invasión vascular (HR: 0.050; IC 95%: 0.008-0.306; p ‹ 0.01) en la biopsia del explante. Conclusión: La sobrevida de los pacientes sometidos a TH por CHC en nuestro centro es similar a lo reportado en la literatura internacional, y se encuentra determinada por el cumplimiento de los CM y la ausencia de invasión vascular en la biopsia del explante.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Ravaioli M, Ercolani G, Neri F, Cescon M, Stacchini G, Del Gaudio M, et al. Liver transplantation for hepatic tumors: a systematic review. World J Gastroenterol. 2014;20:5345-52.

2. Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg. 2015;220:416-27.

3. Figueras J, Jaurrieta E, Valls C, Ramos E, Serrano T, Rafecas A, et al. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg. 2000;190:580-7.

4. Gabrielli M, Vivanco M, Hepp J, Martínez J, Pérez R, Guerra J, et al. Liver transplantation results for hepatocellular carcinoma in Chile. Transplant Proc. 2010;42:299-301.

5. Wan P, Zhang J, Long X, Li Q, Xu N, Zhang M, et al. Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation. Eur J Gastroenterol Hepatol. 2014;26:553-61.

6. De Carlis L, Giacomoni A, Pirotta V, Lauterio A, Slim AO, Sammartino C, et al. Surgical treatment of hepatocellular cancer in the era of hepatic transplantation. J Am Coll Surg. 2003;196:887-97.

7. Tsuchiya K, Asahina Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, et al. Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Liver Transplant. 2014;20:291-7.

8. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzeti F, et al. Carcinomas in patients with cirrhosis. N Engl J Med. 1996;334 693-9.

9. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394-403.

10. Roma J, Balbi E, Pacheco-Moreira L, Zyngier I, Araujo A, Agoglia L, et al. Impact of Model for End-Stage Liver Disease Score on long-term survival following liver transplantation for hepatocellular carcinoma. Transplant Proc. 2012;44:2423-7.

11. Sociedad Chilena de Trasplante. Guía Clínica de Trasplante Hepático. Editorial Sociedad Chilena de Trasplante. Santiago, Chile, 2009.

12. Clavien P, Lesurtel M, Bossuyt P. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:1-21.

13. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transplant. 2003;9:557-63.

14. Sourianarayanane A, El-Gazzaz G, Sanabria JR, Menon KVN, Quintini C, Hashimoto K, et al. Loco-regional therapy in patients with Milan Criteria-compliant hepatocellular carcinoma and short waitlist time to transplant: an outcome analysis. HPB (Oxford). 2012;14:325-32.

15. Kim JM, Kwon CHD, Joh JW, Choi MS, Lee JH, Koh KC, et al. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the milan criteria. Transplant Proc. 2012;44:403-8.

16. Nissen NN, Menon V, Bresee C, Tran TT, Annamalai A, Poordad F, et al. Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient. HPB (Oxford). 2011;13:626-32.

17. Hsieh C-H, Wei C-K, Yin W-Y, Chang C-M, Tsai S-J, Wang L-Y, et al. Vascular invasion affects survival in early hepatocellular carcinoma. Mol Clin Oncol. 2015;3:252-6.

18. Ramanathan R, Sharma A, Lee DD, Behnke M, Bornstein K, Stravitz RT, et al. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. Transplantation. 2014;98:100-6.

19. Choi SH, Lee HH, Lee DS, Choi JH, Heo JS, Lee KW, et al. Clinicopathological features of incidental hepatocellular carcinoma in liver transplantation. Transplant Proc. 2004;36:2293-4.

20. Senkerikova R, Frankova S, Sperl J, Oliverius M, Kieslichova E, Filipova H, et al. Incidental hepatocellular carcinoma: risk factors and long-term outcome after liver transplantation. Transplant Proc. 2014;46:1426-9.

21. Castillo E, Pelletier S, Kumer S, Abouljoud M, Divine G, Moonka D. Incidental hepatocellular carcinoma after liver transplantation: population characteristics and outcomes. Transplant Proc. 2009;41:219-21.

22. Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl. 2011;10:911-8.

23. Sharr WW, Chan SC, Lo C-M. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation. Transplantation. 2014;97(Suppl 8):S10-7.

24. Ramos E, Dalmau A, Sabate A, Lama C, Llado L, Figueras J, et al. Intraoperative red blood cell transfusion in liver transplantation: influence on patient outcome, prediction of requirements, and measures to reduce them. Liver Transplant. 2003;9:1320-7.

25. Boin IFSF, Leonardi MI, Luzo ACM, Cardoso AR, Caruy CA, Leonardi LS. Intraoperative massive transfusion decreases survival after liver transplantation. Transplant Proc. 2008;40:789-91.